Mealey's PI/Product Liability - D.C. Circuit Says FDA Can Regulate Stem Cell Drugs; Company Properly Enjoined

Mealey's PI/Product Liability - D.C. Circuit Says FDA Can Regulate Stem Cell Drugs; Company Properly Enjoined

WASHINGTON, D.C. - The District of Columbia Circuit U.S. Court of Appeals on Feb. 4 said the federal government can regulate a company that cultures stem cells for injection in the donor patient and said a lower court did not err in permanently enjoining the company from violating federal drug regulations (United States of America v. Regenerative Sciences, LLC., et al., No. 12-5254, D.C. Cir.).

Find full version on lexis Advance®
Access this news story on lexis.com®